Moleculin Biotech, Inc. (MBRX) Secures Mexican Patent for Lung-Targeted Annamycin Until 2040

Moleculin Biotech obtained Mexican Patent No. 436849 covering its lung-targeted liposomal Annamycin, with protection through Nov. 23, 2040.Material DetailsContext by AI AnalystThis adds to Moleculin’s ongoing IP build while Annamycin advances in the pivotal MIRACLE AML trial. A clear positive catal…